Santaris Pharma A/S (Formerly Pantheco A/S)

62 articles about Santaris Pharma A/S (Formerly Pantheco A/S)

• Roche Bags Santaris Pharma A/S In Deal Worth $450 Million

  8/5/2014

• Danish Drug Maker Santaris Pharma A/S Considers U.S. Listing

  3/27/2014

• Santaris Pharma A/S, Roche Strike $148 Million+ Alliance To Design And Develop RNA-Targeted Drugs

  1/10/2014

• Santaris Pharma A/S, GlaxoSmithKline Forges Pact To Develop RNA-Targeted Medicines, Financial Details Not Disclosed

  1/10/2014

• Santaris Pharma A/S Announces Appointment Of J. Donald Debethizy As President And Chief Executive Officer

  1/8/2014

• Isarna Therapeutics And Santaris Pharma A/S Announce License Agreement For The Development Of Next Generation Oligonucleotides To Treat TGF-Beta-Mediated Diseases

  1/8/2014

• Santaris Pharma A/S Resumes Full Ownership of Cancer Programs Licensed to Enzon Pharmaceuticals, Inc.

  10/28/2013

• Shire plc and Shire Pharmaceuticals Extends Existing Rare Genetic Disease Pact

  8/23/2013

• RaNA Therapeutics, Inc. and Santaris Pharma A/S Announce Agreement to develop RNA-Targeted Medicines That Selectively Activate Protein Expression

  7/8/2013

• Santaris Pharma A/S Release: EPO Appeal Board Decides in Favor of the Wengel LNA Patent

  4/18/2013

• Santaris Pharma A/S Announces a Worldwide Discovery Alliance With Bristol-Myers Squibb Company for Up to $100 Million

  4/16/2013

• Santaris Pharma A/S Release: USPTO Issues Inter Partes Reexamination Certificate of Key LNA Patent

  4/5/2013

• Research Published in The New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S' Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials

  3/28/2013

• Santaris Pharma A/S and miRagen Therapeutics Expand Worldwide Strategic Alliance to Discover and Develop LNA-Drugs Against Disease Causing Micrornas

  1/8/2013

• USPTO Grants Santaris Pharma A/S' Request for Inter-Partes Reexamination of Patent Licensed to Regulus Therapeutics, Inc.

  1/7/2013

• Court Focuses Patent Suit on Santaris Pharma A/S's Safe Harbor Defense

  9/24/2012

• Santaris Pharma A/S Presents Final Phase 2a Study Results for Miravirsen Showing Dose-Dependent, Prolonged Antiviral Activity in Hepatitis C Patients

  4/19/2012

• United States Patent and Trademark Office Upholds Key Santaris Pharma A/S LNA Patents in Two Re-Examination Cases Brought by Isis Pharmaceuticals, Inc.

  11/30/2011

• Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients

  11/7/2011

• Santaris Pharma A/S to Report New Clinical Data From Miravirsen Phase 2a Study to Treat Hepatitis C in Late-Breaking Oral Presentation at the AASLD 2011 Annual Meeting

  10/3/2011